Part of the Cedars-Sinai Health System, the hospital employs a staff of over 2,000 physicians and 10,000 employees. A team of 2,000 volunteers and more than 40 community groups support a patient-base of over 16,000 people. Over 350 residents and fellows participate in more than 60 graduate medical education programs.
Cedars-Sinai focuses on biomedical research and technologically advanced medical education — based on an interdisciplinary collaboration between physicians and clinical researchers. The facility has research centers covering cardiovascular, genetics, gene therapy, gastroenterology, neuroscience, immunology, surgery, organ transplantation, stem cells, biomedical imaging and cancer — with more than 800 research projects underway (led by 230 Principal Investigators).
Certified as a level I trauma center for adults and pediatrics, Cedars-Sinai trauma-related services range from prevention to rehabilitation and are provided in concert with the hospital’s Department of Surgery. Cedars-Sinai is affiliated with the California Heart Center, University of Southern California and David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
Cedars-Sinai Medical Center research articles from Innovation Toronto
A combination of adult stem cells and parathyroid hormone significantly increased new bone formation in laboratory animals and may speed the healing process for human bone fractures caused by osteoporosis, a new study shows.
The study is published online by Molecular Therapy, a peer-reviewed journal in the Nature Publishing Group. Researchers used a combination of mesenchymal stem cells, which are derived from bone marrow taken from adults, and parathyroid hormone, also called PTH, which regulates human calcium levels essential for strong and healthy bones.
For 21 days, laboratory rats and pigs with vertebral fractures received daily injections of PTH. During the same period, the animals also were injected with five doses of stem cells. The study shows that the combination therapy significantly enhanced the stem cells’ migration to the area of the bone fracture and increased the formation of new, healthy bone.
Effectiveness of Gene Editing in Human Stem Cells Improves Tenfold Using New Technique
For the first time, researchers have employed a gene-editing technique involving low-dose irradiation to edit the genome of patient stem cells, according to a study published in the journal Stem Cells Translational Medicine. This method, developed by researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute, is 10 times more effective than techniques currently in use.
“This novel technique allows for far more efficient gene editing of stem cells and will increase the speed of new discoveries in the field,” said co-senior author Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute.
The irradiation method could prove effective in learning more about diseases such as spinal muscular atrophy, muscular dystrophy and Huntington’s disease. Gene editing allows scientists to correct disease causing mutations and, theoretically, cure the disease in the petri dish. Additionally, gene-editing technology allows scientists to create disease mutations in normal cells, thus modeling human disease.
Cardiologists at the Cedars-Sinai Heart Institute have developed a minimally invasive gene transplant procedure that changes unspecialized heart cells into “biological pacemaker” cells that keep the heart steadily beating.
The laboratory animal research, published online and in today’s print edition of the peer-reviewed journal Science Translational Medicine, is the result of a dozen years of research with the goal of developing biological treatments for patients with heart rhythm disorders who currently are treated with surgically implanted pacemakers. In the United States, an estimated 300,000 patients receive pacemakers every year.
“We have been able, for the first time, to create a biological pacemaker using minimally invasive methods and to show that the biological pacemaker supports the demands of daily life,” said Eduardo Marbán, MD, PhD, director of the Cedars-Sinai Heart Institute, who led the research team. “We also are the first to reprogram a heart cell in a living animal in order to effectively cure a disease.”
Preliminary results show the device, created at Cedars-Sinai and developed by NeuroVision Imaging, may provide highly predictive early detection of changes associated with Alzheimer’s disease
A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer’s disease, according to preliminary results from investigators conducting a clinical trial in Australia.
The researchers will present their findings July 15 in an oral presentation at the Alzheimer’s Association International Conference 2014 in Copenhagen, Denmark. They also were invited by conference organizers to participate in a “breaking news” news conference beginning at 7:30 a.m. Sunday, July 13 in Copenhagen, 1:30 a.m. EDT.